- Home
- ZKH vs MYGN Comparison
ZKH vs MYGN Comparison
Compare ZKH & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZKH
- MYGN
- Stock Information
- Founded
- ZKH 1998
- MYGN 1991
- Country
- ZKH China
- MYGN United States
- Employees
- ZKH N/A
- MYGN N/A
- Industry
- ZKH
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ZKH
- MYGN Health Care
- Exchange
- ZKH Nasdaq
- MYGN Nasdaq
- Market Cap
- ZKH 462.2M
- MYGN 423.1M
- IPO Year
- ZKH 2023
- MYGN 1995
- Fundamental
- Price
- ZKH $2.85
- MYGN $6.97
- Analyst Decision
- ZKH Buy
- MYGN Hold
- Analyst Count
- ZKH 1
- MYGN 13
- Target Price
- ZKH $4.00
- MYGN $13.50
- AVG Volume (30 Days)
- ZKH 33.6K
- MYGN 1.3M
- Earning Date
- ZKH 08-22-2025
- MYGN 11-06-2025
- Dividend Yield
- ZKH N/A
- MYGN N/A
- EPS Growth
- ZKH N/A
- MYGN N/A
- EPS
- ZKH N/A
- MYGN N/A
- Revenue
- ZKH $1,221,845,808.00
- MYGN $832,900,000.00
- Revenue This Year
- ZKH $9.96
- MYGN $0.17
- Revenue Next Year
- ZKH $10.56
- MYGN $6.19
- P/E Ratio
- ZKH N/A
- MYGN N/A
- Revenue Growth
- ZKH N/A
- MYGN 3.83
- 52 Week Low
- ZKH $2.50
- MYGN $3.76
- 52 Week High
- ZKH $4.07
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ZKH 38.82
- MYGN 69.14
- Support Level
- ZKH $2.82
- MYGN $6.40
- Resistance Level
- ZKH $2.96
- MYGN $6.99
- Average True Range (ATR)
- ZKH 0.12
- MYGN 0.35
- MACD
- ZKH -0.00
- MYGN 0.07
- Stochastic Oscillator
- ZKH 33.33
- MYGN 95.60
About ZKH ZKH Group Limited each representing thirty-five (35)
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.